Proteomics tackling schizophrenia as a pathway disorder

Schizophrenia Bulletin

Volumn 38, Issue 6, 2012, Pages 1107-1108

  Martins De Souza, Daniel ^a,b,c  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

mass spectrometry schizophrenia; pathways; proteome; proteomics; systems biology

Indexed keywords

BIOLOGICAL MARKER; PENTOSE PHOSPHATE; TRICARBOXYLIC ACID;

ALZHEIMER DISEASE; AMINO ACID METABOLISM; BIPOLAR DISORDER; CALCIUM HOMEOSTASIS; EDITORIAL; ENDOCYTOSIS; ENERGY METABOLISM; ENVIRONMENTAL FACTOR; FATTY ACID OXIDATION; GENETIC DIFFERENCE; GENETIC VARIABILITY; GLUCONEOGENESIS; GLYCOGEN METABOLISM; GLYCOLYSIS; HUMAN; LIPOGENESIS; MAJOR DEPRESSION; MOLECULAR INTERACTION; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NUCLEOTIDE METABOLISM; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEOMICS; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; UREA CYCLE;

HUMANS; MASS SPECTROMETRY; PROTEOME; PROTEOMICS; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 84869049027     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbs094     Document Type: Editorial

References (12)

1. Sullivan PF. Puzzling over schizophrenia: schizophrenia as a pathway disease. Nat Med. 2012;18:210-211.
2. van Os J, Rutten BP, Poulton R. Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophr Bull. 2008;34:1066-1082.
3. Wilkins MR, Pasquali C, Appel RD, et al. From proteins to proteomes: large scale protein identification by two-dimensional electrophoresis and amino acid analysis. Biotechnology. 1996;14:61-65.
4. Martins-De-Souza D, Dias-Neto E, Schmitt A, et al. Proteome analysis of schizophrenia brain tissue. World J Biol Psychiatry. 2010;11:110-120.
5. Martins-de-Souza D, Harris LW, Guest PC, Bahn S. The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics. Antioxid Redox Signal. 2011;15:2067-2079.
6. Tamminga CA, Thaker GK, Buchanan R, et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry. 1992;49:522-530.
7. Martins-de-Souza D, Guest PC, Harris LW, et al. Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients. Transl Psychiatry. 2012;2:e87.
8. Martins-de-Souza D. Proteome and transcriptome analysis suggests oligodendrocyte dysfunction in schizophrenia. J Psychiatr Res. 2010;44:149-156.
9. Davis KL, Stewart DG, Friedman JI, et al. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry. 2003;60:443-456.
10. Schubert KO, Focking M, Prehn JH, Cotter DR. Hypothesis review: are clathrin-mediated endocytosis and clathrin-dependent membrane and protein trafficking core pathophysiological processes in schizophrenia and bipolar disorder? Mol Psychiatry. 2012.
11. Schwarz E, Izmailov R, Spain M, et al. Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark Insights. 2010;5:39-47.
12. Martins-de-Souza D, Alsaif M, Ernst A, Harris LW, Aerts N, Lenaerts I, Peeters PJ, Amess B, Rahmoune H, Bahn S, Guest PC. The application of selective reaction monitoring confirms dysregulation of glycolysis in a preclinical model of schizophrenia. BMC Res Notes. 2012;5:146.